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A bunch of microRNAs (miRNAs) have been demonstrated to be aberrantly expressed in
cancer tumor tissue and serum. The miRNA signatures identified from the serum samples
could serve as potential noninvasive diagnostic markers for breast cancer. The role of the
miRNAs in cancerigenesis is unclear. In this study, we generated the expression profiles
of miRNAs from the paired breast cancer tumors, normal, tissue, and serum samples
from eight patients using small RNA-sequencing. Serum samples from eight healthy
individuals were used as normal controls. We identified total 174 significantly differentially
expressed miRNAs between tumors and the normal tissues, and 109 miRNAs between
serum from patients and serum from healthy individuals. There are only 10 common
miRNAs. This suggests that only a small portion of tumor miRNAs are released into
serum selectively. Interestingly, the expression change pattern of 28 miRNAs is opposite
between breast cancer tumors and serum. Functional analysis shows that the differentially
expressed miRNAs and their target genes form a complex interaction network affecting
many biological processes and involving in many types of cancer such as prostate cancer,
basal cell carcinoma, acute myeloid leukemia, and more.
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INTRODUCTION
Breast cancer remains one of the leading causes of cancer death
among women worldwide (Siegel et al., 2014). One in every eight
women in the United States will develop breast cancer in her
lifetime (Desantis et al., 2014). Mammography and ultrasound,
as the current standard diagnostic tools, have been successful in
the detection of early-stage breast cancer. However, there is a
need to develop new, minimally invasive diagnostic approaches
to improve diagnosis rates of breast cancer. Recently, microR-
NAs (miRNA), a class of small non-coding RNAs encoded in the
genomes of animals and plants (Carrington and Ambros, 2003;
Bartel, 2004; Asli et al., 2008), have been proposed as promising
biomarkers of early breast cancer diagnosis and accurate prog-
nosis (Schrauder et al., 2012; Chan et al., 2013; Mar-Aguilar
et al., 2013b; Ng et al., 2013). Mature miRNAs are approxi-
mately 22 nt long, and derived from larger 60–110 nt hairpin
precursor transcripts that serve as substrates for the dsRNA
endoribonuclease Dicer (Ke et al., 2003). Active miRNAs reg-
ulates gene expression by controlling stability or translation of
mRNAs through base pairing to partially complementary sites,
predominately in the 3′ untranslated region (UTR) of target
mRNAs (Zhao and Srivastava, 2007). miRNAs are involved in
highly regulated processes such as proliferation, differentiation,
apoptosis and metabolic processes (Pescador et al., 2013), and
contribute significantly to the pathophysiology of breast cancer
by facilitating invasion and metastasis, epithelial to mesenchy-
mal transition, and maintenance of breast stem cells (Ryu et al.,
2011). Dysregulated expression of miRNAs has been potentially
associated with cancers, and these miRNAs can serve as poten-
tial biomarkers for the diagnosis of various cancers and other
diseases (Chen et al., 2008). miRNAs can be readily detected in
tumor biopsies (Jiang et al., 2009) and found stable in serum and
plasma, and other body fluids (Blondal et al., 2013). The previ-
ous study (Mar-Aguilar et al., 2013b) showed that combination of
miR-145, miR-155, and miR-382 could distinguish breast cancer
from normal controls. Currently, more than 2500 mature miR-
NAs have been discovered in mammalian systems and deposited
in the publicly available miRNA database miRBase (Release 20;
http://microrna.sanger.ac.uk/) (Griffiths-Jones, 2010; Kozomara
and Griffiths-Jones, 2014).
To determine the expression pattern of all known miRNAs,
manymethods were developed for miRNA profiling. Quantitative
polymerase chain reaction (qPCR) is a sensitive technique for
estimating expression levels of microRNAs. Jun Lu et al. used a
bead-based flow cytometric miRNA expression profiling method
to classify poorly differentiated tumors and highlighted the
potential of miRNA profiling in cancer diagnosis (Lu et al.,
2005). Analysis of 54 Luminal A-like breast cancer blood sam-
ples and 56 normal blood samples using microarrays (Mcdermott
et al., 2014), indicated that the expression profiles of 3 miRNAs
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(miR-29a, miR-181a, and miR-652), in combination with mam-
mography, has potential to facilitate accurate subtype-specific
breast tumor diagnosis. Recently, next generation sequencing
technologies have been developed to revolutionize miRNA pro-
filing by providing a highly quantitative estimate of known
individual miRNA species (Huang et al., 2009; Dhahbi et al.,
2011; Schotte et al., 2011), as a replacement for microarrays.
Additionally, deep sequencing of miRNAs has the potential for
discovering novel miRNAs, even those that occur at low fre-
quencies (Lu et al., 2009; Ryu et al., 2011; Wei et al., 2013).
However, few studies have compared between serum and tumor
miRNA expression. A recent study (Chan et al., 2013) investi-
gated the miRNA signature of breast cancer tumors (n = 32)
and serum samples (n = 22), and concluded that some miR-
NAs displayed opposite expression pattern in tissue and serum,
previously reported in breast cancer (Cuk et al., 2013).
The objective of this pilot study was to discover a panel of
miRNAs as potential novel breast cancer biomarkers and try
to find the mechanism of miRNA regulation. Thus, we have
used a deep sequencing approach to identify dysregulated miR-
NAs in human breast cancer tissues vs. adjacent tissues and
breast cancer serum vs. serum from healthy female controls. To
investigate the biological functions of the candidate dysregu-
lated miRNAs, downstream miRNA target genes were predicted
using 11 established miRNA target prediction programs stored in
miRecords (http://miRecords.umn.edu/miRecords) (Xiao et al.,
2009). In particular, we have focused on the mechanism
of profiling miRNA expression associated with breast cancer
through examining the expression of their targets, followed by
pathway analyses. Finally, we identified a bunch of miRNA
and their targets that affect breast cancer tumorigenesis and
progression.
MATERIALS AND METHODS
PATIENTS
The patients examined in this study underwent surgery at the
Taizhou Central Hospital between 2012 and 2013. All patients
had not been previously treated by chemotherapy and radio-
therapy when undergoing surgery and provided informed con-
sent to participate in the study. Fresh frozen breast cancer
tumors, adjacent normal tissues, and preoperative serum from
8 patients with breast cancer and control serum sample from 8
healthy female volunteers were obtained from the Taizhou Central
Hospital.
RNA ISOLATION, LIBRARY CONSTRUCTION, AND SEQUENCING
Total RNA was isolated for each of tissue and serum samples and
treated with Trizol reagent (Invitrogen) according to the manu-
facturer’s instructions. The total RNA quantity and purity were
analyzed using Bioanalyzer 2100 and RNA 6000 Nano LabChip
Kit (Agilent). The RIN value is >7.0. To eliminate the biologi-
cal variations caused from the different levels of gene expression
between samples, the RNA from all tumor samples were pooled
together. Similarly, the RNA from all adjacent normal tissue
samples, serum samples were pooled, respectively. Thus, approxi-
mately 1 ug of total pooled RNA were used to prepare small RNA
library according to protocol of TruSeq™ Small RNA Sample Prep
Kits (Illumina). We performed the single-end sequencing (36 bp)
on an Illumina Hiseq2500 at the WS-BIO (Hangzhou, China)
following the vendor’s recommended protocol. Sequencing reads
can be accessed through GEO database under accession number
GSE56614.
READ MAPPING AND DIFFERENTIAL EXPRESSION ANALYSIS
Adapter dimers, junk, low complexity, common RNA families
(rRNA, tRNA, snRNA, snoRNA) and repeats were discarded
followed the procedures as described in a previous study (Li
et al., 2010). Next, small RNA sequencing reads were aligned
against 2578 mature miRNA sequences from miRBase build 20
using Bowtie 1.0.0 (Langmead et al., 2009) allowing at most two
mismatches. The other parameters are default.
Expression values are quantified by aggregating reads into
counts and differential expression analysis is performed based on
normalized deep-sequencing counts in RPM (Reads Per Million
mapped reads) (NOISeq) (Tarazona et al., 2012). The miRNAs
whose expression levels are two or more fold change with q =
0.8 are defined as significantly differentially expressed miRNAs.
Correlations between groups were calculated with Pearson.
PREDICTION OF miRNA TARGETS AND ANALYSIS OF THEIR
EXPRESSION CHANGE
We predicted the targets of the differentially expressed miR-
NAs using the database miRecords (http://mirecords.umn.edu/
miRecords) (Xiao et al., 2009). The target genes were further
filtered by oncomine database that collects cancer microarrays
(http://www.oncomine.org, v4.5) and integrates a data-mining
platform. We only retained the target genes whose expression
changes were at least two fold with p value less than or equal
to 0.05 between human breast cancer and human normal breast
according to the data in oncomine. Moreover, the satisfied expres-
sion change of each gene was supported at least by five datasets in
oncomine.
FUNCTIONAL ANALYSIS OF TARGET GENES
In order to infer the potential functions of the differen-
tially expressed miRNAs, we performed the functional analy-
sis of their target genes using the Database for Annotation,
Visualization, and Integrated Discovery (DAVID) v6.7 (Huang Da
et al., 2009a,b). Functional categories were clustered using the
Functional Annotation Clustering tool, and representative GO
categories and KEGG pathways from each clustered set with a
p-value < 0.05 were selected and taken into consideration for
further analysis.
RESULTS
miRNA EXPRESSION PROFILING OF BREAST CANCER TUMOR AND
SERUM
In order to identify the potential miRNA signatures for breast
cancer detection, we employed RNA-seq to generate the expres-
sion profiles of miRNAs in the paired tumors, normal tissues, and
serum samples from 8 patients. The serum samples from another
8 healthy individuals were used as normal controls for serum.
We obtained more than eight million reads for each sample
(Table S1). The comparison showed that the expression profiles
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of breast cancer tumors and normal tissues were closely correlated
(Pearson r2 = 0.74). In contrast, the expression profiles of serum
from breast cancer patients and from healthy individuals are
much highly correlated (Pearson r2 = 0.98) (Figure 1). Further
examination found 174 significantly differentially expressed miR-
NAs between tumors and normal tissues, 120 miRNAs up-
regulated and 54 down-regulated in tumors. There are 109
significantly differentially expressed miRNAs between the serum
from patients and the serum from healthy individuals, 18 miR-
NAs up-regulated and 91 down-regulated in the serum from
patients. Only 3 up-regulated miRNAs and 7 down-regulated
miRNAs are in common (Table S2). This suggests that miRNAs
may be released into the serum selectively. ThemiRNA expression
profiles change differently in tumors and serum as a consequence
of breast cancer.
Many of the differentially expressed miRNAs have been
reported to involve in cancerogenesis (Table 1). For example, the
previous studies showed that miR-132 (Li et al., 2013), miR-125b
(Zhang et al., 2011), miR-34c (Yang et al., 2013), and miR-485
(Anaya-Ruiz et al., 2013), functioning as suppressors, played an
important role in breast cancer by suppressing cell proliferation
and migration. Notably, miR-382 (Mar-Aguilar et al., 2013b),
miR-224 (Huang et al., 2012), and miR-1246 (Pigati et al., 2010)
were also reported as valuable potential biomarkers of breast can-
cer and diseases. Additionally, miR-598 and miR-184 were also
reported to be down-regulated in esophageal cancer (Zhao et al.,
2013) and prostate cancer (Walter et al., 2013), respectively.
Since there is only a few differentially expressed miRNAs com-
mon to tumors and serum, we further examined the expression
change pattern of the other differentially expressed miRNAs in
tumors and serum. Our results showed that the expression of
28 dysregulated miRNAs was changed differently between breast
cancer tumor tissue and serum (Table 2). Among these miRNAs,
27miRNAs were up-regulated in breast cancer tumors when com-
pared to the normal tissues. In contrast, these 27 miRNAs were
down-regulated in the serum from breast cancer patients when
compared to the serum from healthy individuals. Additionally,
only onemiRNAwas down-regulated in tumors and up-regulated
in the serum from patients. This inconsistent expression change
pattern indicates different molecular mechanisms in the tumors
and the serum because the expression level of their target genes
would be regulated differently.
FIGURE 1 | Correlation analysis of the global miRNAs expression.
(A) The scatter plot of genome-wide miRNA expression between
breast cancer serum between normal serum (Pearson r2 = 0.98),
(B). The scatter plot of genome-wide miRNA expression between
breast cancer tumors between the adjacent normal tissue (Pearson
r2 = 0.74).
Table 1 | Ten miRNAs differentially expressed in both tumor tissue and serum.
miRNA Expression changea miRbase accession number Expression changeb References
miR-132-5p Down MIMAT0004594 Down Li et al., 2013
miR-125b-1-3p Down MIMAT0004592 Down Li et al., 2013; Mar-Aguilar et al., 2013a
miR-34c-5p Down MIMAT0000686 Down Yang et al., 2013
miR-382-3p Down MIMAT0022697 Down Li et al., 2013; Mar-Aguilar et al., 2013b
miR-485-5p Down MIMAT0002175 Down Anaya-Ruiz et al., 2013
miR-323b-3p Down MIMAT0015050 NA NA
miR-598-3p Down MIMAT0003266 NA NA
miR-224-5p Up MIMAT0000281 Up Huang et al., 2012
miR-1246 Up MIMAT0005898 Up Pigati et al., 2010
miR-184 Up MIMAT0000454 NA NA
aExpression change in this study.
bExpression change in the previous studies. NA, Not Available.
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COMPLEX NETWORKS UNDERLYING INTERACTION OF 10 COMMON
miRNAs AND THEIR TARGET TARGETS
We predicted target genes of the 10 common differentially miR-
NAs by at least two algorithms from the miRecords database. We
Table 2 | Inconsistent expression change of 28 miRNAs between
tumor tissue and serum.
miRNA Regulation miRNA Regulation
Serum Tissue Serum Tissue
hsa-miR-370-3p Down Up hsa-miR-455-3p Down Up
hsa-miR-381-3p Down Up hsa-miR-212-5p Down Up
hsa-miR-483-5p Down Up hsa-miR-9-3p Down Up
hsa-miR-125b-5p Down Up hsa-miR-205-5p Down Up
hsa-miR-508-3p Down Up hsa-miR-132-3p Down Up
hsa-miR-9-5p Down Up hsa-miR-432-5p Down Up
hsa-miR-377-3p Down Up hsa-miR-1197 Down Up
hsa-miR-382-5p Down Up hsa-miR-134-5p Down Up
hsa-miR-99a-5p Down Up hsa-miR-539-3p Down Up
hsa-miR-107 Down Up hsa-miR-100-5p Down Up
hsa-miR-485-3p Down Up hsa-miR-500a-3p Down Up
hsa-miR-758-3p Down Up hsa-miR-433-3p Down Up
hsa-miR-497-5p Down Up hsa-miR-504-5p Down Up
hsa-miR-204-5p Down Up hsa-miR-363-3p Up Down
only retained the target genes that were further validated by five
of the 13 separate publications providing mRNA profiling data of
breast cancer tissues in oncomine database.
One miRNA often regulates more than one target genes. A
gene is also often regulated by more than one miRNAs. Therefore,
there is a many-to-many interaction relationship between miR-
NAs and their target genes. Table S3 lists all the potential miRNA-
target interactions which may play an important role in breast
cancer. We further employed Cytoscape, a tool to construct the
miRNA-mRNA interaction network. Our results show a complex
network consisting of the differentially expressed miRNAs and
their target genes (Figure 2).
FUNCTIONAL ANALYSIS OF THE DIFFERENTIALLY EXPRESSED miRNAs
What functions and pathways could be affected by the com-
plex interactions between the miRNAs and their target genes?
To address this issue, we inferred the functions of miRNAs from
their target genes because miRNAs exert their functions through
regulating their target genes. The functional analysis show that
target genes are involved in a variety of positive regulation pro-
cesses like nitrogen compound metabolic process, biosynthetic,
cell motion, cell proliferation, and other biological processes
like hormone metabolic process, mammary gland development,
wound healing and gland development (Figure 3). Further anal-
ysis found that their target genes were enriched in the pathways
FIGURE 2 | Interaction network of the 10 common differentially expressed miRNAs and their target genes in breast cancer. Target genes associated with
only onemiRNA are indicated in dark red. Target genes associatedwithmore than onemiRNAs are indicated in pink. The 10 commonmiRNAs are indicated in blue.
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involved in many cancers including prostate, colorectal, basal
cell carcinoma, acute myeloid leukemia (Figure 4). These results
indicate that these 10 common differentially expressed miRNAs
play a key role in cancerogenesis by impacting various biological
processes.
DISCUSSION
There are only 10 common differentially expressed miRNAs
between breast cancer tumors and the serum (Table S2).
Moreover, the expression change pattern of the differentially
expressed miRNAs is different between the tumors and the serum
(Table 2). These results indicate that only a small portion of miR-
NAs are released into the serum selectively. This is consistent
with the previous study (Chan et al., 2013). To date, at least
four possible different explanations have been proposed for the
origin of serum miRNAs. The first and controversial hypothesis
proposed that miRNAs may originate in large part from cells cir-
culating in the blood (Duttagupta et al., 2011; Pritchard et al.,
2012). However, this proposal has been challenged by other stud-
ies, such as filtering and differential centrifugation experiments
suggesting that miRNAs are not derived from blood cells (Brase
et al., 2010). The second hypothesis is that genetic exchange of
mRNA and miRNA between cells can be accomplished through
microvesicles, or exosome-mediated transfer (Valadi et al., 2007).
Microvesicles are shed from the plasma membrane into the
extracellular environment and released into the blood stream to
facilitate communication between cells. Vesicles released from
human and murine mast cell lines contain over 1200 mRNA and
FIGURE 3 | Top 15 GO terms enriched in the up-and down-regulated target genes of the differentially miRNAs.
FIGURE 4 | KEGG pathways enriched in the up-and down-regulated target genes of the differentially miRNAs by DAVID.
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FIGURE 5 | miR-1246 and miR-485 molecules bind to the target gene.
(A) The alignment between CD59 3′ UTR and miR-1246. (B) The alignment
between CD59 3′ UTR and miR-485.
approximately 121 miRNA molecules, firstly making the con-
nection between microvesicles and miRNA (Valenti et al., 2007).
The third explanation is that passive release occurs during tissue
injury (Brase et al., 2010).The high rate of proliferation and cell
lysis in cancer might contribute to the abundance of miRNAs in
the blood stream. The results presented here establish the foun-
dation to motivate future global investigations of the difference
of miRNA expression between breast cancer tumor tissue and
serum.
The potential for miRNAs as biomarkers in cancer is being
explored, based on the theoretical fact that miRNAs are natu-
ral antisense interactors that regulate many gene associated with
cell survival and proliferation. In this study, we found that CD59,
the cluster of differentiation 59, was a common target of miR-
1246 and miR-485-5p belonging to the 10 differentially expressed
miRNAs (Figure 5). MiRNA target sites in the 3′ UTRs of target
genes were predicted by miRanda algorithm. CD59, also called
protectin, is an 18–20 kD phosphatidylinositol-anchored glyco-
protein that inhibits the cytolytic activity of complement by
binding to C8 and C9, thereby protects the host cell against lysis
by the membrane attack complex (MAC) of homologous comple-
ment (Meri et al., 1990; Li et al., 2011). The loss ofCD59may offer
a selective advantage for breast cancers, resulting in more aggres-
sive tumors (Madjd et al., 2003). In addition to this, a previous
study showed that miR-1246 induced p53-dependent apoptosis
triggered by DNA damage (Palma et al., 2012). Perhaps the over-
expression of miR-1246 alters the CD59 expression profiles in
breast cancer, resulting in cell apoptosis. Unfortunately, the inter-
action between CD59 and miR-1246 has not been verified. On the
other hand, miR-485 was also found to act as a tumor suppres-
sor by affecting the proliferation rates and cell migration of breast
carcinoma T47D cells (Anaya-Ruiz et al., 2013). Collectively, these
results indicate that down-expression of miR-485 facilitates the
expression ofCD59, thereby improving the proliferation rates and
cell migration of breast cancer cells. Because miRNAs can regulate
cell-fate decisions, we concluded that miR-1246 andmiR-485may
regulate the apoptotic vs. proliferative phenotype of breast cancer
cells.
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